Elea's owners buy Brazil's Cellera Farma, eye Latin America's largest pharma market
What's the deal? The shareholders of Elea, one of Argentina's largest pharmaceutical companies, have acquired 90% of Brazilian drugmaker Cellera Farma. The deal marks Elea's entry into Brazil — Latin America's biggest pharma market.
Cellera's founder, Omilton Visconde Junior, retains a 10% stake and continues as chief executive officer. The sellers were private equity firm Victoria Capital Partners, which held 79.9%, and Visconde Junior's brother, who held 10%.
The transaction value was not disclosed due to a confidentiality agreement, but industry sources told Valor Econômico that Cellera's enterprise value may have reached $300M when factoring in a new deal with Sanofi.
Why now? Alongside the ownership change, Cellera announced a four-year distribution and commercialisation agreement with Sanofi for two medicines in Brazil. That contract — which includes a purchase option — will add US$166.3M in annual revenue, effectively doubling Cellera's sales to US$332.6M per year.
"Entering Brazil was an aspiration of many years. It's the largest market in the region, with very competitive and competent companies," said Daniel Sielecki, a director and shareholder of Elea.
Elea generates between $700M and $800M in annual revenue. The Sielecki family, which controls the Argentine group, also has interests in oil and gas, petrochemicals, and natural gas transport. At least two Elea executives — including family member Mathias Sielecki — are relocating to Brazil to join Cellera's team.
What could go wrong? Brazil's pharmaceutical market is known for fierce competition, which Elea's leadership acknowledged. Integrating an Argentine parent's strategy with a Brazilian operation adds cross-border complexity — from regulation to currency risk. And the Sanofi contract, while transformative, runs only four years; if it is not renewed or the purchase option not exercised, Cellera's revenue base could shrink sharply.
The signal: The deal reflects growing appetite among Latin American pharma players to consolidate across borders rather than wait for a multinational acquirer. Cellera, founded only in 2017 with private equity backing, built a portfolio of recognisable brands like Tylex (painkiller) and Pamelor (antidepressant) — making it an attractive platform for regional expansion. Brazil's antitrust body, Cade, has already approved the transaction, clearing the path for execution.
For Elea, the acquisition is a bet that operational know-how from Argentina's competitive market can translate into growth in a much larger neighbour. For Victoria Capital Partners, it represents a full exit from a startup-to-scaleup pharma play in under a decade.
Read more: valor.globo.com
